水包油包纳米粒亚微乳剂的研究
|
摘要
增加难溶性药物的溶解度是药剂学研究的热点之一,而油水均不溶性药物给药系统的研究更是其中的难点问题。本课题将纳米粒和水包油(O/W)亚微乳相结合,制成新型的水包油包纳米粒(N/O/W)亚微乳给药系统,将纳米粒包载在亚微乳的油相中,以达到增加制剂中难溶性药物载药量的目的。制剂中采用生物相容性好的辅料,安全性好,可实现难溶性药物的静脉注射给药。N/O/W亚微乳可进一步制成干乳剂,提高稳定性不好的药物在制剂中的稳定性。双氢青蒿素(Dihydroartemisinin,DHA)是青蒿素经还原而成的半缩醛化合物,具有良好的抗疟作用,近代研究表明DHA对多种人类和动物肿瘤细胞均有杀伤作用,且治疗浓度下对正常细胞几乎无毒性作用,有希望发展成为新型的抗肿瘤药物。DHA为难溶性药物,分子结构中存在特殊的过氧基团,稳定性差,胃肠道降解严重,生物利用度低。本研究以双氢青蒿素为模型药物,采用生物相容性好的辅料制备了注射用DHAN/O/W亚微乳剂,可实现DHA的静脉注射给药。同时针对DHA稳定性不好的特点,进一步制成干乳剂,提高DHA在制剂中的稳定性。
本课题建立了DHA的HPLC含量测定法,考察了DHA在溶液中异构体的转化平衡情况,α-DHA与β-DHA在溶液中达到平衡所需时间约为10h,平衡后二者的比例不再变化,比例约为2.3(α/β)。在转化过程中DHA异构体总峰面积基本保持恒定,对DHA的HPLC分析可用α-DHA与β-DHA峰面积之和与浓度进行线性回归,计算DHA的含量。测定了DHA在不同溶媒中的溶解度,DHA在水和大豆油中的表观溶解度分别为0.119±0.021和1.24±0.01mg/mL,在水和大豆油中加入不同乳化剂后,均能提高DHA的溶解度,其中以大豆油/大豆磷脂/胆固醇最为显著。
以注射用大豆油、大豆磷脂、胆固醇和稳定剂C为油相,Poloxamer188、甘油为水相,采用微射流技术制备DHA N/O/W亚微乳。乳剂外观为乳白色液体,无油花,不挂壁,用水稀释后有淡蓝色乳光。平均粒径为152±18nm(PDI0.078±0.018),Zeta电位为-33.28±2.07mV,pH值为7.18±0.03,符合注射要求。DHA N/O/W亚微乳中药物含量为2.98±0.03mg/mL,载药量约为DHA O/W亚微乳最高载药量的3倍。以DHAO/W亚微乳作为对照,分别在光学显微镜、透射电镜、冷冻蚀刻透射电镜下观察不同粒径DHAN/O/W亚微乳的形态。结果显示,DHAN/O/W亚微乳呈椭圆状,边缘光滑,乳滴大小较均匀,乳滴中包含有颗粒状物质,DHA O/W亚微乳中则未观察到有颗粒状物质存在。冷冻蚀刻透射电镜可见DHAN/O/W亚微乳乳滴断面不平整,具有类似于层纹或壳状的结构存在,而DHA O/W亚微乳的乳滴断面较光滑平坦。以多种可代表DHA纳米粒不同状态的DHA制剂和DHA纯品为对照,进行DHA N/O/W亚微乳的DSC分析试验。与DHA纯品相比,DHA N/O/W亚微乳剂和DHA油混悬液中DHA的熔点下降了接近10℃。而DHA水混悬液和模拟DHA分散在N/O/W亚微乳水相的制剂中DHA熔点与DHA纯品的熔点相近。通过DHA的熔点变化情况判断,DHAN/O/W亚微乳剂中DHA的存在位置应在制剂的油相中,与显微镜的结构观察结果相符。
考察了DHA在N/O/W亚微乳中的分布情况。经测定DHA N/O/W亚微乳剂约有8.06%的药物溶解在水相中,91.9%的药物存在在油相中。其中有13.8%的药物溶解在油相中,其余78.1%的DHA存在于界面膜和油相的纳米粒中。
以甘露醇:蔗糖(4:1)为冻干保护剂制备了DHA N/O/W干乳剂,干乳中冻干保护剂与油相的比例为2:1(w/w)。冻干过程为DHA N/O/W亚微乳与冻干保护剂混合均匀后,在-40℃迅速冷却预冻6小时,然后在-40℃真空干燥4小时,-40℃～0℃真空干燥8小时,升温至20℃持续4小时去除残余水分,冻于过程中压力保持在30-50mTorr,冷凝器温度控制在-80℃。
建立了DHA有关物质的HPLC分析法,采用强制破坏法制备了在强酸、强碱、光照、高温和氧化条件下破坏的样品,找到了7个DHA的降解产物。DHA的降解产物在本分析方法下均能达到良好分离,本法可用于DHA制剂的稳定性研究。
考察了DHA、DHAN/O/W亚微乳剂和DHAN/O/W干乳剂的稳定性。结果表明,DHA对光照和高温敏感,在湿度较高的环境下含量也有改变,故应低温干燥避光保存。考察了DHA在溶液中的稳定情况。与DHA溶液相比,DHA N/O/W亚微乳的稳定性已有提高,但对温度仍然很敏感,在光照条件下不稳定。DHAN/O/W亚微乳需放置在4℃,充氮避光密闭保存。对DHA N/O/W干乳剂进行了加速试验和长期留样观察。DHA N/O/W干乳经25℃、60%RH加速试验6个月,含量下降4%,复溶时间略微延长,粒径分布、Zeta电位和pH值没有显著变化。4℃长期留样观察9个月内制剂性状、药物含量等均无明显变化。在此条件下DHAN/O/W干乳剂质量稳定,长期试验仍在进行中。
通过异常毒性检查、血管刺激性试验以及溶血性试验对DHA N/O/W亚微乳剂的安全性进行了初步评价。DHA N/O/W亚微乳剂对小鼠的异常毒性试验合格,制剂在生产过程中未带来异常的毒性。对家兔耳缘静脉无明显刺激作用,对家兔红细胞无明显体外溶血及致凝集作用,DHA N/O/W亚微乳剂用于静脉注射是安全的。
建立了体内样品中DHA含量测定的HPLC-MS分析方法。方法专属性好,内源性杂质对样品测定无干扰,样品处理简单,精密度、回收率均符合规定,可用于DHA的体内分析。以DHA和DHA O/W亚微乳剂为对照,考察了DHAN/O/W亚微乳剂与家兔、大鼠和人血浆的血浆蛋白结合情况。在本试验研究的浓度范围内,不同浓度的DHA制剂在同种血浆中的蛋白结合率无显著差异,蛋白结合率与药物浓度无关。不同制剂在同种血浆中的蛋白结合率也没有显著差异。不同种血浆当中,DHA与家兔的血浆蛋白结合率较高,其次为大鼠和人的,DHA与血浆蛋白具有中等强度的结合,平均血浆蛋白结合率分别76.36%、66.34%和63.94%。
家兔体内药动学研究结果显示,DHA N/O/W亚微乳和DHA O/W亚微乳可以显著延长DHA的体内循环时间,提高血浆中药物浓度。DHA N/O/W亚微乳和DHA O/W亚微乳的MRT分别为DHA溶液剂的的10.39和3.42倍,DHAN/O/W亚微乳为DHA O/W亚微乳的3.03倍。DHA N/O/W亚微乳和DHA O/W亚微乳的AUC分别为DHA溶液剂的3.01和1.80倍,DHA N/O/W亚微乳为DHAO/W亚微乳的1.67倍。小鼠组织分布研究表明,DHA在体内迅速转化成一未知成分,在血液样品中可观察到转变情况,各组织中仅检测到该成分的存在。经固相萃取分离提取,HPLC-MS分析得到该成分的质谱图,该成分具有m/z 267.1的碎片离子峰提示其结构中仍有过氧基团的存在,应仍具有与DHA类似的药效。考察了该成分在小鼠体内的消除分布规律,研究DHA N/O/W亚微乳剂的组织分布趋势。结果表明,DHA亚微乳剂可延长药物在体内组织脏器中的滞留时间,在肝的摄取最高。DHA N/O/W亚微乳剂和DHA O/W亚微乳剂的体内分布趋势有所不同,DHA N/O/W亚微乳剂在心脏的分布降低,而在血中的滞留时间和在胃、脑中的分布增加。
以H_(22)荷瘤小鼠模型进行DHA N/O/W亚微乳剂抗肿瘤药效学的研究。乳剂给药剂量为45mg/kg时,抑瘤率达51.8%(P＜0.01),给药剂量为11.25mg/kg时,抑瘤率为23.0%,低剂量乳剂组药效略高于同等剂量的溶液组,高剂量的溶液对照组给药后溶媒毒性超过了动物的耐受剂量,因此未得到高剂量溶液组的数据。结果表明,45mg/kg的DHA N/O/W亚微乳剂对H_(22)肿瘤细胞具有显著抑制效果。对小鼠肿瘤的免疫组化结果分析表明,DHA可下调VEGF的表达,高剂量乳剂组尤为明显,对各组组织切片的MVD观察结果表明,MVD与VEGF表达结果趋势相同,DHA可能是通过抑制肿瘤细胞的血管生成来抑制肿瘤的生长。
通过DHAN/O/W亚微乳的处方与工艺筛选、制剂特征、稳定性、安全性考察,动物组织分布、体内药物动力学、以及抗肿瘤作用的研究,表明N/O/W亚微乳具有以下优点:(1)可提高油水均不溶性药物的载药量;(2)使用生物相容性好的辅料,制剂安全性好,可适用于静脉注射给药;(3)以亚微乳作为纳米粒的载体,可增加纳米制剂的物理稳定性;(4)可进一步制成干乳剂,增加不稳定药物的化学稳定性;(5)能够改变药物在体内的组织分布和药物动力学性质,有可能进一步开发成靶向制剂;(6)易于工业化生产。本课题为N/O/W亚微乳新剂型的研究奠定了基础,为难溶性药物给药系统的研发提供新思路。DHA N/O/W亚微乳的研究可为疟疾重症患者提供急救用药,同时也可为研发双氢青蒿素抗肿瘤作用新用途提供制剂。
The way to increase the solubility of poorly soluble drugs is concerned in recent years.Both poorly water-soluble and poorly oil-soluble drugs are faced with a major challenge in dosage form development.In this study,nanoparticle and emulsion were designed and put together to prepare a novel emulsion which have both the advantages of nanoparticle and emulsion.An nanoparticle-in-oil-in-water(N/O/W) submicron emulsion was prepared with physiological excipients and achieved intravenous administration of poorly soluble drugs.Nanoparticles were incorporated in the oil phase of O/W emulsion to enhance the drug loading capacity of N/O/W emulsion.Furthermore,this novel emulsion could be converted into dry emulsion to increase the stablity of unstable drugs.
Dihydroartemisinin(DHA)is the lactol reduction product of artemisinin and found to be effective against acute malaria and chloroquine resistant strains of falciparum malaria.In recent years,DHA has been proven to have potent antitumor activity, well-tolerated and relative non-toxicity in vitro and in vivo.DHA kills tumor cells under the therapeutic dose while common cells partly increased.These findings show that DHA offer great potential and a promising approach in the treatment of cancer, particularly in view of the relative non-toxicity.DHA is a poorly soluble drug in both water and oil and unstable under various conditions.DHA would be serious degraded in gastrointestinal tract.These properties restricts the application of its administration. In this study,DHA was used as a model drug and DHA N/O/W emulsion was prepared for intraveous administration of DHA.Furthermore,DHA N/O/W dry emulsion was prepared to increase the stablity of DHA.
The method of high performance liquid chromatography(HPLC)was set up to determine the concentration of DHA.DHA exsist as a mixture of a andβanomers in solution and the ratio of a versusβremained constant after the equilibrium of the andβanomers had been reached.In our study,the ratio of a versusβremained constant around 2.3(α/β)and did not vary over a period of 10 h.The peak area of DHA could be calculated as the sum of a andβanomer to assure the correct results. The solubility of DHA in different solvents were also determined.The apparent solubility of DHA in distilled water and soybean oil was 0.119±0.021 and 1.24±0.01 mg/ml,respectively.The solubility could be enhanced by adding different emulsifiers into systems.The most effective one is Soybean Oil/SPL/Chol.
DHA N/O/W emulsion containing DHA,soybean oil,SPL,stabilizer C and cholesterol as oily phase and Poloxamer 188 and glycerol as aqueous phase were prepared by microfluid technology.The DHA N/O/W emulsion were characterized and its droplet size,zeta potential and pH were 152±18 nm(PDI 0.078±0.018), -33.28±2.07 mV,and 7.18±0.03,respectively.The drug loading capacity of DHA N/O/W emulsion was 2.98±0.03 mg/ml and was nearly 3 times more than the highest concentration of DHA O/W emulsion.Light microscopy,Transmission electron microscopy(TEM)and Freeze-fracture transmission electron microscopy(FF-TEM) were used for the observation of DHA N/O/W emulsion structure and compared with DHA O/W emulsion.There were some particles existed in the oil droplets of N/O/W emulsion while not in O/W emulsion.We also used FF-TEM method to observe the internal structure of DHA N/O/W emulsion and compared with DHA O/W emulsion. Thermal analysis was performed to study the characterization of N/O/W emulsion. Compared with DHA powder,the endothermic peak of DHA N/O/W emulsion and DHA oil nanosuspension were decreased nearly 10 centi-degree,while the endothermic peak of DHA aqueous nanosuspension and the mixture of DHA aqueous nanosuspension and blank N/O/W emulsion were similar to DHA powder's.These results indicated that DHA nanoparticles were exsited in the oil phase of DHA N/O/W emulsion,which was conformed to the microscopy micrographs of DHA N/O/W emulsion.About 91.94%of DHA located in oil phase of DHA N/O/W emulsion. About 13.83%of DHA dissolved in oil phase and 8.06%dissolved in aqueous phase. Most of DHA distributed in the interface and nanoparticles(～78.11%).
The lyophilized emulsion was developed to improve the stability of DHA N/O/W emulsion.Screening from various cryopotectants,Sucrose-mannitol(4:1)was optimized as a mixture of cryopotectants for DHA N/O/W emulsion.The ratio of cryopotectant and oil phase was 2:1(w/w).The emulsions were freezed at -40℃for 6 h,primary drying at -40℃for 4 hours,from-40℃to 0℃for 8 hours,and secondary drying at 20℃for 4 hours to allow for a complete solidification.The chamber pressure was maintained at 30-50 mTorr while the condenser temperature remained at -80℃during the drying process.
A HPLC method was established to determine DHA and its related substances by optimizing the mobile phase.The samples in destroy tests of acid,alkali,strong light, heat and oxygen were prepared.We found and detected 7 decomposable compounds under different destroy conditions.This method was simple,sensitive and suitable for the determation of the related substances of DHA for its stability study.
The stability of DHA,DHA N/O/W emulsion and DHA N/O/W dry emulsion were investigated.The chemical raw medicine of DHA was extremly unstable under strong light and heat condition.It was also not stable in high humidity environment and should be stored in a dry and light-proof enviroment with low temperature.The stability of DHA N/O/W emulsion was better than DHA solution,while it was still sensitive with strong light and heat.It should be stored at 4℃and fullfilled with N_2. The accelerated test of DHA N/O/W dry emulsion at 25℃,60%RH and long stability test at 4℃indicated that DHA N/O/W dry emulsion should be stored in a dry and light-proof enviroment at 4℃.
The safety of DHA N/O/W emulsion was evaluted by abnormally toxic test,blood vessel irritation test and hemolysis test.The results indicated that DHA N/O/W emulsion had neither serious intravenous toxicity nor undesirable irritation to veins and no stimulation on blood vessel of rabbits,no hemolysis and agglomeration on vitro body red cells of rabbit.DHA N/O/W emulsion has no hemolysis and stimulative reaction.The pharmaceutical safety of DHA N/O/W emulsion was confirmed.
To further understand and reveal the case of DHA N/O/W emulsion in vivo,a HPLC-MS method for determining DHA was developed.This method was simple, sensitive and suitable for the determation of DHA in biological samples.The plasma protein binding rate of DHA was determined with ultraflitration.The plasma protein binding rate of DHA with rabbit,rat and human plasma were 76.36%,66.34%and 63.94%,respectively.The binding rate of DHA with plasma is midding strength.
After intraveous administration of DHA N/O/W emulsion,DHA O/W emulsion and DHA solution to rabbit,pharmacokinetics parameters were calculated.It turned out that DHA N/O/W emulsion and O/W emulsion significantly prolonged MRT of DHA.DHA N/O/W emulsion and O/W emulsion could extend the MRT of DHA solution by 10.39 and 3.42 times,when AUC was enhanced by 3.01 and 1.80 times, respectively.The biodistribution test was carried out on ICR mice.DHA N/O/W emulsion enhanced DHA content in plasma,stomach and brain,while decreased the ditribution in heart.
Experimental tumor H_(22)mice was used to observe the anti-tumor effect of DHA on tumor growth.The tumor inhibitory rate of DHA N/O/W emulsion(45 mg/kg)group is 51.8%,which was better than other DHA different doses groups(P＜0.01).DHA N/O/W emulsion(45 mg/kg)can significantly inhibit H_(22)growth.The expression of VEGF and MVD were down regulated.Histopathological examination showed the tumor inhibition of DHA might related to the inhibition of angiogenesis in tumor.
In this study,the physicochemical characteristics,stablility,safety test,and antitumor effect of DHA N/O/W emulsion were studied.The results show that this novel formulation has the following advantages:(1)Increasing drug-loaded capability of emulsion for the drugs which solubility are both poorly in oils and in water;(2) N/O/W emulsion was prepared with physiological excipients and achieved intravenous administration;(3)Submicron emulsion as carriers of nanoparticles can restrain nanoparticles aggregate with each other,and this can improve formulation's physical stability;(4)N/O/W emulsion can be further converted into dry emulsion for unstable drugs;(5)The pharmacokinetics and biodistribution could be changed and possible to be developed as a targeted agent;(6)ease of manufacture.We provide some academic and experimental data for DHA intraveous administration and N/O/W emulsion as carrier of poor solubility drugs.The study of DHA N/O/W emulsion could provided an emergency medicine for patients with severe malaria and a promising approach in the study of cancer treatment.
本课题建立了DHA的HPLC含量测定法,考察了DHA在溶液中异构体的转化平衡情况,α-DHA与β-DHA在溶液中达到平衡所需时间约为10h,平衡后二者的比例不再变化,比例约为2.3(α/β)。在转化过程中DHA异构体总峰面积基本保持恒定,对DHA的HPLC分析可用α-DHA与β-DHA峰面积之和与浓度进行线性回归,计算DHA的含量。测定了DHA在不同溶媒中的溶解度,DHA在水和大豆油中的表观溶解度分别为0.119±0.021和1.24±0.01mg/mL,在水和大豆油中加入不同乳化剂后,均能提高DHA的溶解度,其中以大豆油/大豆磷脂/胆固醇最为显著。
以注射用大豆油、大豆磷脂、胆固醇和稳定剂C为油相,Poloxamer188、甘油为水相,采用微射流技术制备DHA N/O/W亚微乳。乳剂外观为乳白色液体,无油花,不挂壁,用水稀释后有淡蓝色乳光。平均粒径为152±18nm(PDI0.078±0.018),Zeta电位为-33.28±2.07mV,pH值为7.18±0.03,符合注射要求。DHA N/O/W亚微乳中药物含量为2.98±0.03mg/mL,载药量约为DHA O/W亚微乳最高载药量的3倍。以DHAO/W亚微乳作为对照,分别在光学显微镜、透射电镜、冷冻蚀刻透射电镜下观察不同粒径DHAN/O/W亚微乳的形态。结果显示,DHAN/O/W亚微乳呈椭圆状,边缘光滑,乳滴大小较均匀,乳滴中包含有颗粒状物质,DHA O/W亚微乳中则未观察到有颗粒状物质存在。冷冻蚀刻透射电镜可见DHAN/O/W亚微乳乳滴断面不平整,具有类似于层纹或壳状的结构存在,而DHA O/W亚微乳的乳滴断面较光滑平坦。以多种可代表DHA纳米粒不同状态的DHA制剂和DHA纯品为对照,进行DHA N/O/W亚微乳的DSC分析试验。与DHA纯品相比,DHA N/O/W亚微乳剂和DHA油混悬液中DHA的熔点下降了接近10℃。而DHA水混悬液和模拟DHA分散在N/O/W亚微乳水相的制剂中DHA熔点与DHA纯品的熔点相近。通过DHA的熔点变化情况判断,DHAN/O/W亚微乳剂中DHA的存在位置应在制剂的油相中,与显微镜的结构观察结果相符。
考察了DHA在N/O/W亚微乳中的分布情况。经测定DHA N/O/W亚微乳剂约有8.06%的药物溶解在水相中,91.9%的药物存在在油相中。其中有13.8%的药物溶解在油相中,其余78.1%的DHA存在于界面膜和油相的纳米粒中。
以甘露醇:蔗糖(4:1)为冻干保护剂制备了DHA N/O/W干乳剂,干乳中冻干保护剂与油相的比例为2:1(w/w)。冻干过程为DHA N/O/W亚微乳与冻干保护剂混合均匀后,在-40℃迅速冷却预冻6小时,然后在-40℃真空干燥4小时,-40℃～0℃真空干燥8小时,升温至20℃持续4小时去除残余水分,冻于过程中压力保持在30-50mTorr,冷凝器温度控制在-80℃。
建立了DHA有关物质的HPLC分析法,采用强制破坏法制备了在强酸、强碱、光照、高温和氧化条件下破坏的样品,找到了7个DHA的降解产物。DHA的降解产物在本分析方法下均能达到良好分离,本法可用于DHA制剂的稳定性研究。
考察了DHA、DHAN/O/W亚微乳剂和DHAN/O/W干乳剂的稳定性。结果表明,DHA对光照和高温敏感,在湿度较高的环境下含量也有改变,故应低温干燥避光保存。考察了DHA在溶液中的稳定情况。与DHA溶液相比,DHA N/O/W亚微乳的稳定性已有提高,但对温度仍然很敏感,在光照条件下不稳定。DHAN/O/W亚微乳需放置在4℃,充氮避光密闭保存。对DHA N/O/W干乳剂进行了加速试验和长期留样观察。DHA N/O/W干乳经25℃、60%RH加速试验6个月,含量下降4%,复溶时间略微延长,粒径分布、Zeta电位和pH值没有显著变化。4℃长期留样观察9个月内制剂性状、药物含量等均无明显变化。在此条件下DHAN/O/W干乳剂质量稳定,长期试验仍在进行中。
通过异常毒性检查、血管刺激性试验以及溶血性试验对DHA N/O/W亚微乳剂的安全性进行了初步评价。DHA N/O/W亚微乳剂对小鼠的异常毒性试验合格,制剂在生产过程中未带来异常的毒性。对家兔耳缘静脉无明显刺激作用,对家兔红细胞无明显体外溶血及致凝集作用,DHA N/O/W亚微乳剂用于静脉注射是安全的。
建立了体内样品中DHA含量测定的HPLC-MS分析方法。方法专属性好,内源性杂质对样品测定无干扰,样品处理简单,精密度、回收率均符合规定,可用于DHA的体内分析。以DHA和DHA O/W亚微乳剂为对照,考察了DHAN/O/W亚微乳剂与家兔、大鼠和人血浆的血浆蛋白结合情况。在本试验研究的浓度范围内,不同浓度的DHA制剂在同种血浆中的蛋白结合率无显著差异,蛋白结合率与药物浓度无关。不同制剂在同种血浆中的蛋白结合率也没有显著差异。不同种血浆当中,DHA与家兔的血浆蛋白结合率较高,其次为大鼠和人的,DHA与血浆蛋白具有中等强度的结合,平均血浆蛋白结合率分别76.36%、66.34%和63.94%。
家兔体内药动学研究结果显示,DHA N/O/W亚微乳和DHA O/W亚微乳可以显著延长DHA的体内循环时间,提高血浆中药物浓度。DHA N/O/W亚微乳和DHA O/W亚微乳的MRT分别为DHA溶液剂的的10.39和3.42倍,DHAN/O/W亚微乳为DHA O/W亚微乳的3.03倍。DHA N/O/W亚微乳和DHA O/W亚微乳的AUC分别为DHA溶液剂的3.01和1.80倍,DHA N/O/W亚微乳为DHAO/W亚微乳的1.67倍。小鼠组织分布研究表明,DHA在体内迅速转化成一未知成分,在血液样品中可观察到转变情况,各组织中仅检测到该成分的存在。经固相萃取分离提取,HPLC-MS分析得到该成分的质谱图,该成分具有m/z 267.1的碎片离子峰提示其结构中仍有过氧基团的存在,应仍具有与DHA类似的药效。考察了该成分在小鼠体内的消除分布规律,研究DHA N/O/W亚微乳剂的组织分布趋势。结果表明,DHA亚微乳剂可延长药物在体内组织脏器中的滞留时间,在肝的摄取最高。DHA N/O/W亚微乳剂和DHA O/W亚微乳剂的体内分布趋势有所不同,DHA N/O/W亚微乳剂在心脏的分布降低,而在血中的滞留时间和在胃、脑中的分布增加。
以H_(22)荷瘤小鼠模型进行DHA N/O/W亚微乳剂抗肿瘤药效学的研究。乳剂给药剂量为45mg/kg时,抑瘤率达51.8%(P＜0.01),给药剂量为11.25mg/kg时,抑瘤率为23.0%,低剂量乳剂组药效略高于同等剂量的溶液组,高剂量的溶液对照组给药后溶媒毒性超过了动物的耐受剂量,因此未得到高剂量溶液组的数据。结果表明,45mg/kg的DHA N/O/W亚微乳剂对H_(22)肿瘤细胞具有显著抑制效果。对小鼠肿瘤的免疫组化结果分析表明,DHA可下调VEGF的表达,高剂量乳剂组尤为明显,对各组组织切片的MVD观察结果表明,MVD与VEGF表达结果趋势相同,DHA可能是通过抑制肿瘤细胞的血管生成来抑制肿瘤的生长。
通过DHAN/O/W亚微乳的处方与工艺筛选、制剂特征、稳定性、安全性考察,动物组织分布、体内药物动力学、以及抗肿瘤作用的研究,表明N/O/W亚微乳具有以下优点:(1)可提高油水均不溶性药物的载药量;(2)使用生物相容性好的辅料,制剂安全性好,可适用于静脉注射给药;(3)以亚微乳作为纳米粒的载体,可增加纳米制剂的物理稳定性;(4)可进一步制成干乳剂,增加不稳定药物的化学稳定性;(5)能够改变药物在体内的组织分布和药物动力学性质,有可能进一步开发成靶向制剂;(6)易于工业化生产。本课题为N/O/W亚微乳新剂型的研究奠定了基础,为难溶性药物给药系统的研发提供新思路。DHA N/O/W亚微乳的研究可为疟疾重症患者提供急救用药,同时也可为研发双氢青蒿素抗肿瘤作用新用途提供制剂。
The way to increase the solubility of poorly soluble drugs is concerned in recent years.Both poorly water-soluble and poorly oil-soluble drugs are faced with a major challenge in dosage form development.In this study,nanoparticle and emulsion were designed and put together to prepare a novel emulsion which have both the advantages of nanoparticle and emulsion.An nanoparticle-in-oil-in-water(N/O/W) submicron emulsion was prepared with physiological excipients and achieved intravenous administration of poorly soluble drugs.Nanoparticles were incorporated in the oil phase of O/W emulsion to enhance the drug loading capacity of N/O/W emulsion.Furthermore,this novel emulsion could be converted into dry emulsion to increase the stablity of unstable drugs.
Dihydroartemisinin(DHA)is the lactol reduction product of artemisinin and found to be effective against acute malaria and chloroquine resistant strains of falciparum malaria.In recent years,DHA has been proven to have potent antitumor activity, well-tolerated and relative non-toxicity in vitro and in vivo.DHA kills tumor cells under the therapeutic dose while common cells partly increased.These findings show that DHA offer great potential and a promising approach in the treatment of cancer, particularly in view of the relative non-toxicity.DHA is a poorly soluble drug in both water and oil and unstable under various conditions.DHA would be serious degraded in gastrointestinal tract.These properties restricts the application of its administration. In this study,DHA was used as a model drug and DHA N/O/W emulsion was prepared for intraveous administration of DHA.Furthermore,DHA N/O/W dry emulsion was prepared to increase the stablity of DHA.
The method of high performance liquid chromatography(HPLC)was set up to determine the concentration of DHA.DHA exsist as a mixture of a andβanomers in solution and the ratio of a versusβremained constant after the equilibrium of the andβanomers had been reached.In our study,the ratio of a versusβremained constant around 2.3(α/β)and did not vary over a period of 10 h.The peak area of DHA could be calculated as the sum of a andβanomer to assure the correct results. The solubility of DHA in different solvents were also determined.The apparent solubility of DHA in distilled water and soybean oil was 0.119±0.021 and 1.24±0.01 mg/ml,respectively.The solubility could be enhanced by adding different emulsifiers into systems.The most effective one is Soybean Oil/SPL/Chol.
DHA N/O/W emulsion containing DHA,soybean oil,SPL,stabilizer C and cholesterol as oily phase and Poloxamer 188 and glycerol as aqueous phase were prepared by microfluid technology.The DHA N/O/W emulsion were characterized and its droplet size,zeta potential and pH were 152±18 nm(PDI 0.078±0.018), -33.28±2.07 mV,and 7.18±0.03,respectively.The drug loading capacity of DHA N/O/W emulsion was 2.98±0.03 mg/ml and was nearly 3 times more than the highest concentration of DHA O/W emulsion.Light microscopy,Transmission electron microscopy(TEM)and Freeze-fracture transmission electron microscopy(FF-TEM) were used for the observation of DHA N/O/W emulsion structure and compared with DHA O/W emulsion.There were some particles existed in the oil droplets of N/O/W emulsion while not in O/W emulsion.We also used FF-TEM method to observe the internal structure of DHA N/O/W emulsion and compared with DHA O/W emulsion. Thermal analysis was performed to study the characterization of N/O/W emulsion. Compared with DHA powder,the endothermic peak of DHA N/O/W emulsion and DHA oil nanosuspension were decreased nearly 10 centi-degree,while the endothermic peak of DHA aqueous nanosuspension and the mixture of DHA aqueous nanosuspension and blank N/O/W emulsion were similar to DHA powder's.These results indicated that DHA nanoparticles were exsited in the oil phase of DHA N/O/W emulsion,which was conformed to the microscopy micrographs of DHA N/O/W emulsion.About 91.94%of DHA located in oil phase of DHA N/O/W emulsion. About 13.83%of DHA dissolved in oil phase and 8.06%dissolved in aqueous phase. Most of DHA distributed in the interface and nanoparticles(～78.11%).
The lyophilized emulsion was developed to improve the stability of DHA N/O/W emulsion.Screening from various cryopotectants,Sucrose-mannitol(4:1)was optimized as a mixture of cryopotectants for DHA N/O/W emulsion.The ratio of cryopotectant and oil phase was 2:1(w/w).The emulsions were freezed at -40℃for 6 h,primary drying at -40℃for 4 hours,from-40℃to 0℃for 8 hours,and secondary drying at 20℃for 4 hours to allow for a complete solidification.The chamber pressure was maintained at 30-50 mTorr while the condenser temperature remained at -80℃during the drying process.
A HPLC method was established to determine DHA and its related substances by optimizing the mobile phase.The samples in destroy tests of acid,alkali,strong light, heat and oxygen were prepared.We found and detected 7 decomposable compounds under different destroy conditions.This method was simple,sensitive and suitable for the determation of the related substances of DHA for its stability study.
The stability of DHA,DHA N/O/W emulsion and DHA N/O/W dry emulsion were investigated.The chemical raw medicine of DHA was extremly unstable under strong light and heat condition.It was also not stable in high humidity environment and should be stored in a dry and light-proof enviroment with low temperature.The stability of DHA N/O/W emulsion was better than DHA solution,while it was still sensitive with strong light and heat.It should be stored at 4℃and fullfilled with N_2. The accelerated test of DHA N/O/W dry emulsion at 25℃,60%RH and long stability test at 4℃indicated that DHA N/O/W dry emulsion should be stored in a dry and light-proof enviroment at 4℃.
The safety of DHA N/O/W emulsion was evaluted by abnormally toxic test,blood vessel irritation test and hemolysis test.The results indicated that DHA N/O/W emulsion had neither serious intravenous toxicity nor undesirable irritation to veins and no stimulation on blood vessel of rabbits,no hemolysis and agglomeration on vitro body red cells of rabbit.DHA N/O/W emulsion has no hemolysis and stimulative reaction.The pharmaceutical safety of DHA N/O/W emulsion was confirmed.
To further understand and reveal the case of DHA N/O/W emulsion in vivo,a HPLC-MS method for determining DHA was developed.This method was simple, sensitive and suitable for the determation of DHA in biological samples.The plasma protein binding rate of DHA was determined with ultraflitration.The plasma protein binding rate of DHA with rabbit,rat and human plasma were 76.36%,66.34%and 63.94%,respectively.The binding rate of DHA with plasma is midding strength.
After intraveous administration of DHA N/O/W emulsion,DHA O/W emulsion and DHA solution to rabbit,pharmacokinetics parameters were calculated.It turned out that DHA N/O/W emulsion and O/W emulsion significantly prolonged MRT of DHA.DHA N/O/W emulsion and O/W emulsion could extend the MRT of DHA solution by 10.39 and 3.42 times,when AUC was enhanced by 3.01 and 1.80 times, respectively.The biodistribution test was carried out on ICR mice.DHA N/O/W emulsion enhanced DHA content in plasma,stomach and brain,while decreased the ditribution in heart.
Experimental tumor H_(22)mice was used to observe the anti-tumor effect of DHA on tumor growth.The tumor inhibitory rate of DHA N/O/W emulsion(45 mg/kg)group is 51.8%,which was better than other DHA different doses groups(P＜0.01).DHA N/O/W emulsion(45 mg/kg)can significantly inhibit H_(22)growth.The expression of VEGF and MVD were down regulated.Histopathological examination showed the tumor inhibition of DHA might related to the inhibition of angiogenesis in tumor.
In this study,the physicochemical characteristics,stablility,safety test,and antitumor effect of DHA N/O/W emulsion were studied.The results show that this novel formulation has the following advantages:(1)Increasing drug-loaded capability of emulsion for the drugs which solubility are both poorly in oils and in water;(2) N/O/W emulsion was prepared with physiological excipients and achieved intravenous administration;(3)Submicron emulsion as carriers of nanoparticles can restrain nanoparticles aggregate with each other,and this can improve formulation's physical stability;(4)N/O/W emulsion can be further converted into dry emulsion for unstable drugs;(5)The pharmacokinetics and biodistribution could be changed and possible to be developed as a targeted agent;(6)ease of manufacture.We provide some academic and experimental data for DHA intraveous administration and N/O/W emulsion as carrier of poor solubility drugs.The study of DHA N/O/W emulsion could provided an emergency medicine for patients with severe malaria and a promising approach in the study of cancer treatment.
引文
[1]LIPINSKI,C.A.(2000).Drug-like properties and the causes of poor solubility and poor permeability.J Pharmacol Toxicol Methods 44(1):235-249.
[2]LIPINSKI,C.A.,LOMBARDO,R,DOMINY,B.W.,FEENEY,P.J.(2001).Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev 46(1-3):3-26.
[3]STRICKLEY,R.G(2004).Solubilizing excipients in oral and injectable formulations.Pharm Res 21(2):201-230.
[4]BUGGINS,T.R.,DICKINSON,P.A.,TAYLOR,G(2007).The effects of pharmaceutical excipients on drug disposition.Adv Drug Deliv Rev 59(15):1482-1503.
[5]MAHMUD,A.,XIONG.,X.B.,ALIABADI,H.M.,LAVASANIFAR,A.(2007).Polymeric micelles for drug targeting.J Drug Target 15(9):553-584.
[6]STELLA,V.J.,HE,Q.(2008).Cyclodextrins.Toxicol Pathol 36(1):30-42.
[7]METSELAAR,J.M.,MASTROBATTISTA,E.,STORM,G(2002).Liposomes for intravenous drug targeting:design and applications.Mini Rev Med Chem 2(4):319-329.
[8]DRISCOLL,D.F.(2006).Lipid injectable emulsions:2006.Nutr Clin Pract 21(4):381-386.
[9]BANSAL,T.,MUSTAFA,G.,KHAN,Z.I.,AHMAD,F.J.,KHAR,R.K.,TALEGAONKAR,S.(2008).Solid self-nanoemulsifying delivery systems as a platform technology for formulation of poorly soluble drugs.Crit Rev Ther Drug Carrier Syst 25(1):63-116.
[10]KECK,C.M.,MULLER,R.H.(2006).Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.Eur J Pharm Biopharm 62(1):3-16.
[11]VAN EERDENBRUGH,B.,VAN DEN MOOTER,G.,AUGUSTIJNS,P.(2008).Top-down production of drug nanocrystals:nanosuspension stabilization,miniaturization and transformation into solid products.Int J Pharm 364(1):64-75.
[12]WONG.,J.,BRUGGER,A.,KHARE,A.,CHAUBAL,M.,PAPADOPOULOS,P.,RABINOW,B.,KIPP,J.,NING.,J.(2008).Suspensions for intravenous(IV)injection:a review of development,preclinical and clinical aspects.Adv Drug Deliv Rev 60(8):939-954.
[13]MERISKO-LIVERSIDGE,E.,LIVERSIDGE,G(2008).Drug nanoparticles:formulating poorly water-soluble compounds.Toxicol Pathol 36(1):43-48.
[14]FAHR,A.,LIU,X.(2007).Drug delivery strategies for poorly water-soluble drugs.Expert Opin Drug Deliv 4(4):403-416.
[15]NISHIYAMA,N.,KATAOKA,K.(2006).Current state,achievements,and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.Pharmacol Ther 112(3):630-648.
[16]ATTWOOD,D.,ZHOU,Z.,BOOTH,C.(2007).Polyethylene oxide)based copolymers:solubilisation capacity and gelation.Expert Opin Drug Deliv 4(5): 533-546.
[17]MULLER,R.H.,MADER,K.,GOHLA,S.(2000).Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art.Eur J Pharm Biopharm 50(1):161-177.
[18]MULLER,R.H.,RADTKE,M.,WISSING,S.A.(2002).Nanostructured lipid matrices for improved microencapsulation of drugs.Int J Pharm 242(1-2):121-128.
[19]LASIC,D.D.,PAPAHADJOPOULOS,D.(1995).Liposomes revisited.Science 267(5202):1275-1276.
[20]RIAZ,M.(1995).Review article:stability and uses of liposomes.Pak J Pharm Sci 8(2):69-79.
[21]DATE,A.A.,NAGARSENKER,M.S.(2008).Parenteral microemulsions:an overview.Int J Pharm 355(1-2):19-30.
[22]HAYNES,R.K.(2006).From artemisinin to new artemisinin antimalarials:biosynthesis,extraction,old and new derivatives,stereochemistry and medicinal chemistry requirements.Curr Top Med Chem 6(5):509-537.
[23](1982).Studies on the toxicity of qinghaosu and its derivatives.China Cooperative Research Group on qinghaosu and its derivatives as antimalarials.J Tradit Chin Med 2(1):31-38.
[24]MYINT,H.Y.,ASHLEY,E.A.,DAY,N.P.,NOSTEN,F.,WHITE,N.J.(2007).Efficacy and safety of dihydroartemisinin-piperaquine.Trans R Soc Trop Med Hyg 101(9):858-866.
[25]KLAYMAN,D.L.(1985).Qinghaosu(artemisinin):an antimalarial drug from China.Science 228(4703):1049-1055.
[26]GRACE,J.,AGUILAR,A.,TROTMAN,K.,PEGGINS,J.,BREWER,T.(1998).Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450.Drug Metab Dispos 26(4):313-317.
[27]JUNG,M.,LEE,K.,KIM,H.,PARK,M.(2004).Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents.Curr Med Chem 11(10):1265-1284.
[28]曹智刚,袁守军,陈惠鹏,徐兰平,田增月,韩昌明,丁林茂(2006).双氢青蒿素对肿瘤细胞及肿瘤动物模型的抑制作用.期医学杂志(24).
[29]EFFERTH,T.,MARSCHALL,M.,WANG,X.,HUONG,S.M.,HAUBER,I.,OLBRICH,A.,KRONSCHNABL,M.,STAMMINGER,T.,HUANG,E.S.(2002).Antiviral activity of artesunate towards wild-type,recombinant,and ganciclovir-resistant human cytomegaloviruses.J Mol Med 80(4):233-242.
[30]SUN,W.C.,HAN,J.X.,YANG,W.Y.,DENG,D.A.,YUE,X.F.(1992).[Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro].Zhongguo Yao Li Xue Bao 13(6):541-543.
[31]SINGH,N.P.,LAI,H.(2001).Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells.Life Sci 70(1):49-56.
[32]SADAVA,D.,PHILLIPS,T.,LIN,C.,KANE,S.E.(2002).Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells.Cancer Lett 179(2):151-156.
[33]WANG,Z.S.,CAO,X.L.(1988).[Studies on mutarotation and anomeric conversion of dihydroqinghaosu].Yao Xue Xue Bao 23(8):610-615.
[34]董顺玲,胡家炽,张玉英,张焕宜(1996).高效液相色谱法测定双氢青蒿素含量.药物分析杂志(03).
[35]赵文志,白志川,段淼(2007).双氢青蒿素的指纹图谱研究.中外健康文摘(临床医药版)(06).
[36]HU,F.Q.,JIANG,S.P.,DU,Y.Z.,YUAN,H.,YE,Y.Q.,ZENG,S.(2006).Preparation and characteristics of monostearin nanostructured lipid carriers.Int J Pharm 314(1):83-89.
[37]TONGCHER,O.,SIGEL,R.,LANDFESTER,K.(2006).Liquid crystal nanoparticles prepared as miniemulsions.Langmuir 22(10):4504-4511.
[38]OKOCHI,H.,NAKANO,M.(2000).Preparation and evaluation of w/o/w type emulsions containing vancomycin.Adv Drug Deliv Rev 45(1):5-26.
[39]BENITA,S.,LEVY,M.Y.(1993).Submicron emulsions as colloidal drug carriers for intravenous administration:comprehensive physicochemical characterization.J Pharm Sci 82(11):1069-1079.
[40]SUGIURA,S.,NAKAJIMA,M.,YAMAMOTO,K.,IWAMOTO,S.,ODA,T.,SATAKE,M.,SEKI,M.(2004).Preparation characteristics of water-in-oil-in-water multiple emulsions using microchannel emulsification.Journal of Colloid and Interface Science 270(1):221-228.
[41]WEBER,C.H.,CHICHE,A.,KRAUSCH,G,ROSENFELDT,S.,BALLAUFF,M.,HARNAU,L.,GOTTKER-SCHNETMANN,I.,TONG,Q.,MECKING,S.(2007).Single lamella nanoparticles of polyethylene.Nano Lett 7(7):2024-2029.
[42]GAO,Y.,LI,N.,HILFERT,L.,ZHANG,S.,ZHENG,L.,YU,L.(2009).Temperature-induced microstructural changes in ionic liquid-based microemulsions.Langmuir 25(3):1360-1365.
[43]YI,T.,WAN,J.,XU,H.,YANG,X.(2008).A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs.Eur J Pharm Biopharrn 70(2):439-444.
[44]LI,F.,WANG,T.,HE,H.B.,TANG,X.(2008).The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization.Int J Pharm 349(1-2):291-299.
[45]ABDELWAHED,W.,DEGOBERT,G.,STAINMESSE,S.,FESSI,H.(2006).Freeze-drying of nanoparticles:formulation,process and storage considerations.Adv Drug Deliv Rev 58(15):1688-1713.
[46]NAIL,S.L.,HER,L.M.,PROFFITT,C.P.,NAIL,L.L.(1994).An improved microscope stage for direct observation of freezing and freeze drying.Pharm Res 11(8):1098-1100.
[47]ZHANG,L.,LIU,L.,QIAN,Y.,CHEN,Y.(2008).The effects of cryoprotectants on the freeze-drying of ibuprofen-loaded solid lipid microparticles(SLM).Eur J Pharm Biopharm 69(2):750-759.
[48]NAVARATNAM,V.,MORDI,M.,MANSOR,S.(1997).Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies.J Chromatogr B Biomed Sci Appl 692(1):157-162.
[49]NAIK,H.,MURRY,D.,KIRSCH,L.,FLECKENSTEIN,L.(2005).Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci 816(1-2):233-242.
[50]RAJANIKANTH,M.,MADHUSUDANAN,K.,GUPTA,R.(2003).An HPLC-MS method for simultaneous estimation of alpha,beta-arteether and its metabolite dihydroartemisinin,in rat plasma for application to pharmacokinetic study.Biomed Chromatogr 17(7):440-446.
[51]SOUPPART,C.,GAUDUCHEAU,N.,SANDRENAN,N.,RICHARD,F.(2002).Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci 774(2):195-203.
[52]SINGH,N.,LAI,H.Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells.Anticancer Res 25(6B):4325-4331.
[53]GABOUREL,J.D.(1972).Drug-protein interactions and their clinical significance.Adv Biol Skin 12:51-60.
[54]COLUSSI,D.,PARISOT,C.,LEGAY,F.,LEFEVRE,G(1999).Binding of artemether and lumefantrine to plasma proteins and erythrocytes.Eur J Pharm Sci 9(1):9-16.
[55]ZHANG H.Y,TANG.,X.,LI,H.Y,LIU,X.L.(2008).A lipid microsphere vehicle for vinorelbine:Stability,safety and pharmacokinetics.Int J Pharm 348(1-2):70-79.
[56]WEIDNER,N.(1995).Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.Breast Cancer Res Treat 36(2):169-180.
[1]TAKINO,T.,KONISHI,K.,TAKAKURA,Y,HASHIDA,M.(1994).Long circulating emulsion carrier systems for highly lipophilic drugs.Biol Pharm Bull 17(1):121-125.
[2]NAKANO,M.(2000).Places of emulsions in drug delivery.Adv Drug Deliv Rev 45(1):1-4.
[3]FLORENCE,A.T.,WHITEHILL,D.(1982).Stabilization of water/oil/water multiple emulsions by polymerization of the aqueous phases.J Pharm Pharmacol 34(11):687-691.
[4]CLAUSSE,D.,GOMEZ,F.,DALMAZZONE,C.,NOIK,C.(2005).A method for the characterization of emulsions,thermogranulometry:Application to water-in-crude oil emulsion.Journal of Colloid and Interface Science 287(2):694-703.
[5]NAKHARE,S.,VYAS,S.P.(1995).Prolonged release of rifampicin from multiple w/o/w emulsion systems.J Microencapsul 12(4):409-415.
[6]NAKHARE,S.,VYAS,S.P.(1996).Preparation and characterization of multiple emulsion based systems for controlled diclofenac sodium release.J Microencapsul 13(3):281-292.
[7]HOU,W.,PAPADOPOULOS,K.D.(1997).W1/0/W2 and O1/W/02 globules stabilized with Span 80 and Tween 80.Colloids and Surfaces A:Physicochemical and Engineering Aspects 125(2-3):181-187.
[8]YOSHIDA,K.,SEKINE,T.,MATSUZAKI,F.,YANAKI,T.,YAMAGUCHI,M.(1999).Stability of vitamin A in oil-in-water-in-oil-type multiple emulsions.Journal of the American Oil Chemists' Society 76(2):1-6.
[9]GARTI,N.(1998).New trends in double emulsions for controlled release.In The Colloid Science of Lipids,pp.83-92.
[10]JUNGINGER,H.E.(1984).Colloidal structures of O/W creams.Pharm Weekbl Sci 6(4):141-149.
[11]LEVY,M.Y,SCHUTZE,W.,FUHRER,C.,BENITA,S.(1994).Characterization of diazepam submicron emulsion interface:role of oleic acid.J Microencapsul 11(1):79-92.
[12]URSICA,L.,TITA,D.,PALICI,I.,TITA,B.,VLAIA,V.(2005).Particle size analysis of some water/oil/water multiple emulsions.J Pharm Biomed Anal 37(5):931-936.
[13]WANGQI,H.,PAPADOPOULOS,K.D.(1996).Stability of water-in-oil-in-water type globules.Chemical Engineering Science 51(22):5043-5051.
[14]VASILJEVIC.,D.,PAROJCIC.,J.,PRIMORAC.,M.,VULETA,G.(2006).An investigation into the characteristics and drug release properties of multiple W/O/W emulsion systems containing low concentration of lipophilic polymeric emulsifier.International Journal of Pharmaceutics 309(1-2):171-177.
[15]MINORU TOMITA,Y A.,TAMOTSU KONDO,(1982).Viscosity change after dilution with solutions of water-oil-water emulsions and solute permeability through the oil layer.Journal of Pharmaceutical Sciences 71(3):332-334.
[16]OZER,O.,BALOGLU,E.,ERTAN,G.,MUGUET,V.,YAZAN,Y.(2000).The effect of the type and the concentration of the lipophilic surfactant on the stability and release kinetics of the W/O/W multiple emulsions.Int J Cosmet Sci 22(6):459-470.
[17]OZER,O.,MUGUET,V.,ROY,E.,GROSSIORD,J.L.,SEILLER,M.(2000).Stability study of W/O/W viscosified multiple emulsions.Drug Dev Ind Pharm 26(11):1185-1189.
[18]TOKGOZ,N.S.,GROSSIORD,J.L.,FRUCTUS,A.,SEILLER,M.,PROGNON,P.(1996).Evaluation of two fluorescent probes for the characterization of W/O/W emulsions.International Journal of Pharmaceutics 141(1-2):27-37.
[19]HINO,T.,SHIMABAYASHI,S.,TANAKA,M.,NAKANO,M.,OKOCHI,H.(2001).Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase.J Microencapsul 18(1):19-28.
[20]HILLS,B.P.,MANOJ,P.,DESTRUEL,C.(2000).NMR Q-space microscopy of concentrated oil-in-water emulsions.Magn Reson Imaging 18(3):319-333.
[21]HILLS,B.P.,TANG.,H.R.,MANOJ,P.,DESTRUEL,C.(2001).NMR diffusometry of oil-in-water emulsions.Magn Reson Imaging 19(3-4):449-451.
[22]NORDEN,T.P.,SIEKMANN,B.,LUNDQUIST,S.,MALMSTEN,M.(2001).Physicochemical characterisation of a drug-containing phospholipid-stabilised o/w emulsion for intravenous administration.Eur J Pharm Sci 13(4):393-401.
[23]TERRISSE,I.,SEILLER,M.,RABARON,A.,GROSSIORD,J.L.,MAGNET,A.,HEN-FERRENBACH,C.(1993).Rheology:how to characterize and to predict the evolution of W/O/W multiple emulsions.Int J Cosmet Sci 15(2):53-62.
[24]KAWASHIMA,Y,NIWA,T.,TAKEUCHI,H.,HINO,T.,ITOH,Y,FURUYAMA,S.(1991).Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques.J Pharm Sci 80(5):472-478.
[25]NAKHARE,S.,VYAS,S.P.(1997).Multiple emulsion based systems for prolonged delivery of rifampicin:in vitro and in vivo characterization.Pharmazie 52(3):224-226.
[26]AXEL BENICHOU,A.A.(2007).Recent Developments in O/W/O Multiple Emulsions.In Multiple Emulsions(A.ABRAHAM editor),pp.165-207.
[27]JIM JIAO,D.J.B.(2007).Multiple Emulsion Stability:Pressure Balance and Interfacial Film Strength.In Multiple Emulsions(A.ABRAHAM editor),pp.1-27.
[28]BJERREGAARD,S.,S ERBERG.,I.,VERMEHREN,C.,FROKJAER,S.(1999).Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design.International Journal of Pharmaceutics 193(1):1-11.
[29]N.GARTI(1998).A new approach to improved stability and controlled release in double emulsions,by the use of graft-comb polymeric amphiphiles.Acta Polymerica 49(10-11):606-616.
[30]DAVIS,S.S.,WALKER,I.(1983).Measurement of the yield of multiple emulsion droplets by a fluorescent tracer technique.International Journal of Pharmaceutics 17(2-3):203-213.
[31]OMOTOSHO,J.A.,WHATELEY,T.L.,LAW,T.K.,FLORENCE,A.T.(1986).The nature of the oil phase and the release of solutes from multiple(w/o/w)emulsions. J Pharm Pharmacol 38(12):865-870.
[32]SHIMA,M.,TANAKA,M.,KIMURA,Y.,ADACHI,S.,MATSUNO,R.(2004).Hydrolysis of the oil phase of a W/O/W emulsion by pancreatic lipase.J Control Release 94(1):53-61.
[33]ANNETT KNOTH,I.S.,GERALD MUSCHIOLIK,(2005).Effect of lipid type on water-in-oil-emulsions stabilized by phosphatidylcholine-depleted lecithin and polyglycerol polyricinoleate.European Journal of Lipid Science and Technology 107(12):857-863.
[34]KHAN,A.Y.,TALEGAONKAR,S.,IQBAL,Z.,AHMED,F.J.,KHAR,R.K.(2006).Multiple emulsions:an overview.Curr Drug Deliv 3(4):429-443.
[35]LINDENSTRUTH,K.,MULLER,B.W.(2004).W/O/W multiple emulsions with diclofenac sodium.European Journal of Pharmaceutics and Biopharmaceutics 58(3):621-627.
[36]SHIMA,M.,KOBAYASHI,Y.,FUJII,T.,TANAKA,M.,KIMURA,Y.,ADACHI,S.,MATSUNO,R.(2004).Preparation of fine W/O/W emulsion through membrane filtration of coarse W/O/W emulsion and disappearance of the inclusion of outer phase solution.Food Hydrocolloids 18(1):61-70.
[37]VAN DER GRAAF,S.,SCHRO,C.G.P.H.,BOOM,R.M.(2005).Preparation of double emulsions by membrane emulsification--a review.Journal of Membrane Science 251(1-2):7-15.
[38]BRODIN,A.F.,KAVALIUNAS,D.R.,FRANK,S.G.(1978).Prlonged drug release from multiple emulsions.Acta Pharm Suec 15(1):1-12.
[39]ALLOUCHE,J.,TYRODE,E.,SADTLER,V.,CHOPLIN,L.,SALAGER,J.-L.(2003).Single-and Two-Step Emulsification To Prepare a Persistent Multiple Emulsion with a Surfactant−Polymer Mixture.Industrial & Engineering Chemistry Research 42(17):3982-3988.
[40]LINDENSTRUTH,K.,MULLER,B.W.(2004).W/O/W multiple emulsions with diclofenac sodium.Eur J Pharm Biopharm 58(3):621-627.
[41]FUKUSHIMA,S.,JUNI,K.,NAKANO,M.(1983).Preparation of and drug release from W/O/W type double emulsions containing anticancer agents.Chem Pharm Bull(Tokyo) 31(11):4048-4056.
[42]FUKUSHIMA,S.,NISHIDA,M.,NAKANO,M.(1987).Preparation of and drug release from W/O/W type double emulsions containing anticancer agents using an oily lymphographic agent as an oil phase.Chem Pharm Bull(Tokyo) 35(8):3375-3381.
[43]OKOCHI,H.,NAKANO,M.(2000).Preparation and evaluation of w/o/w type emulsions containing vancomycin.Adv Drug Deliv Rev 45(1):5-26.
[44]JOSCELYNE,S.M.,DH,G.(2000).Membrane emulsification--a literature review.Journal of Membrane Science 169(1):107-117.
[45]KUKIZAKI,M.,GOTO,M.(2007).Preparation and evaluation of uniformly sized solid lipid microcapsules using membrane emulsification.Colloids and Surfaces A:Physicochemical and Engineering Aspects 293(1-3):87-94.
[46]HIGASHI,S.,TABATA,N.,KONDO,K.H.,MAEDA,Y.,SHIMIZU,M.,NAKASHIMA,T.,SETOGUCHI,T.(1999).Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma.J Pharmacol Exp Ther 289(2):816-819.
[47]SUGIURA,S.,NAKAJIMA,M.,YAMAMOTO,K.,IWAMOTO,S.,ODA,T.,SATAKE,M.,SEKI,M.(2004).Preparation characteristics of water-in-oil-in-water multiple emulsions using microchannel emulsification.Journal of Colloid and Interface Science 270(1):221-228.
[48]WHITEHILL,D.,FLORENCE,A.T.(1979).Mechanisms of instability in W/O/W multiple emulsions [proceedings].J Pharm Pharmacol 31 Suppl:3P.
[49]ZHANG.,W.,MIYAKAWA,T.,UCHIDA,T.,GOTO,S.(1992).[Preparation of stable W/O/W type multiple emulsion containing water-soluble drugs and in vitro evaluation of its drug-releasing properties].Yakugaku Zasshi 112(1):73-80.
[50]MUGUET,V.,SEILLER,M.,BARRATT,G.,OZER,O.,MARTY,J.P.,GROSSIORD,J.L.(2001).Formulation of shear rate sensitive multiple emulsions.J Control Release 70(1-2):37-49.
[51]VAZIRI,A.,WARBURTON,B.(1994).Slow release of chloroquine phosphate from multiple taste-masked W/O/W multiple emulsions.J Microencapsul 11(6):641-648.
[52]VAZIRI,A.,WARBURTON,B.(1995).Improved stability of w/o/w multiple emulsions by addition of hydrophilic colloid components in the aqueous phases.J Microencapsul 12(1):1-5.
[53]FECHNER,A.,KNOTH,A.,SCHERZE,I.,MUSCHIOLIK,G.(2007).Stability and release properties of double-emulsions stabilised by caseinate-dextran conjugates.Food Hydrocolloids 21(5-6):943-952.
[54]BJERREGAARD,S.,S ERBERG.,I.,VERMEHREN,C.,FROEKJAER,S.(1999).The effect of controlled osmotic stress on release and swelling properties of a water-in-oil emulsion.International Journal of Pharmaceutics 183(1):17-20.
[55]KAWASHIMA,Y,NIWA,T,TAKEUCHI,H.,HINO,T.,ITO,Y.(1992).Control of prolonged drug release and compression properties of ibuprofen microspheres with acrylic polymer,eudragit RS,by changing their intraparticle porosity [corrected].Chem Pharm Bull(Tokyo)40(1):196-201.
[56]HINO,T,SHIMABAYASHI,S.,TANAKA,M.,NAKANO,M,OKOCHI,H.(2001).Improvement of encapsulation efficiency of water-in-oil-inwater emulsion with hypertonic inner aqueous phase.Journal of Microencapsulation 18(1):19-28.
[57]HINO,T,KAWASHIMA,Y,SHIMABAYASHI,S.(2000).Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy.Advanced Drug Delivery Reviews 45(1):27-45.
[58]FLORENCE,A.T,ROGERS,J.A.(1971).Emulsion stabilization by non-ionic surfactants:experiment and theory.J Pharm Pharmacol 23(A):233-251 concl.
[59]FLORENCE,A.T,ROGERS,J.A.(1971).Emulsion stabilization by non-ionic surfactants:experiment and theory.J Pharm Pharmacol 23(3):153-169 contd.
[60]OPAWALE,F.O.,BURGESS,D.J.(1998).Influence of interfacial rheological properties of mixed emulsifier films on the stability of water-in-oil-in-water emulsions.J Pharm Pharmacol 50(9):965-973.
[61]OPAWALE,F.O.,BURGESS,D.J.(1998).Influence of Interfacial Properties of Lipophilic Surfactants on Water-in-Oil Emulsion Stability.J Colloid Interface Sci 197(1):142-150.
[62]JIAO,J.,BURGESS,D.J.(2003).Rheology and stability of water-in-oil-in-water multiple emulsions containing Span 83 and Tween 80.AAPS PharmSci 5(1):E7.
[63]OMOTOSHO,J.A.,WHATELEY,T.L.,FLORENCE,A.T.(1989).Release of 5-fluorouracil from intramuscular w/o/w multiple emulsions.Biopharm Drug Dispos 10(3):257-268.
[64]OMOTOSHO,J.A.,WHATELEY,T.L.,FLORENCE,A.T.(1989).Methotrexate transport from the internal phase of multiple w/o/w emulsions.J Microencapsul 6(2):183-192.
[65]JIAO,J.,RHODES,D.G.,BURGESS,D.J.(2002).Multiple emulsion stability:pressure balance and interfacial film strength.J Colloid Interface Sci 250(2):444-450.
[66]MYERS,S.L.,SHIVELY,M.L.(1993).Solid-state emulsions:the effects of maltodextrin on microcrystalline aging.Pharm Res 10(9):1389-1391.
[67]SHIVELY,M.L.,MYERS,S.(1993).Solid-state emulsions:the effects of process and storage conditions.Pharm Res 10(7):1071-1075.
[68]IWAMOTO,K.,KATO,T.,KAWAHARA,M.,KOYAMA,N.,WATANABE,S.,MIYAKE,Y,SUNAMOTO,J.(1991).Polysaccharide-coated oil droplets in oil-in-water emulsions as targetable carriers for lipophilic drugs.J Pharm Sci 80(3):219-224.
[69]JAGER-LEZER,N.,TERRISSE,I.,BRUNEAU,F.,TOKGOZ,S.,FERREIRA,L.,CLAUSSE,D.,SEILLER,M.,GROSSIORD,J.L.(1997).Influence of lipophilic surfactant on the release kinetics of water-soluble molecules entrapped in a W/O/W multiple emulsion.Journal of Controlled Release 45(1):1-13.
[70]KHOPADE,A.J.,JAIN,N.K.(1998).A stable multiple emulsion system bearing isoniazid:preparation and characterization.Drug Dev Ind Pharm 24(3):289-293.
[71]KHOPADE,A.J.,JAIN,N.K.(1998).Effects of drug concentration in inner aqueous phase and additives in oleaginous phase on release and bioavailability of isoniazid from multiple emulsion.Drug Dev Ind Pharm 24(7):677-680.
[72]KAWASHIMA,Y,CUI,F.,TAKEUCHI,H.,NIWA,T.,HINO,T.,KIUCHI,K.(1995).Improved static compression behaviors and tablettabilities of spherically agglomerated crystals produced by the spherical crystallization technique with a two-solvent system.Pharm Res 12(7):1040-1044.
[73]SHIAU,Y F.(1981).Mechanisms of intestinal fat absorption.Am J Physiol 240(1):G1-9.
[74]PORTER,C.J.,CALIPH,S.M.,CHARMAN,W.N.(1997).Differences in preand post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma.J Pharm Biomed Anal 16(1):175-180.
[75]ONYEJI,C.,OMOTOSHO,J.,OGUNBONA,F.(1991).Increased gastro-intestinal absorption of griseofulvin from w/o/w emulsions.
[76]ONYEJI,C.,ADESEGUN,S.(1995).Influence of viscosity on nitrofurantoin absorption from w/o/w emulsions.
[77]ENGEL,R.H.,RIGGI,S.J.,FAHRENBACH,M.J.(1968).Insulin:intestinal absorption as water-in-oil-in-water emulsions.Nature 219(5156):856-857.
[78]SUZUKI,A.,MORISHITA,M.,KAJITA,M.,TAKAYAMA,K.,ISOWA,K.,CHIBA,Y,TOKIWA,S.,NAGAI,T.(1998).Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid.J Pharm Sci 87(10):1196-1202.
[79]MATSUZAWA,A.,MORISHITA,M.,TAKAYAMA,K.,NAGAI,T.(1995).Absorption of insulin using water-in-oil-in-water emulsion from an enteral loop in rats.Biol Pharm Bull 18(12):1718-1723.
[80]TOORISAKA,E.,ONO,H.,ARIMORI,K.,KAMIYA,N.,GOTO,M.(2003).Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water(S/O/W)emulsion.Int J Pharm 252(1-2):271-274.
[81]SHIVELY,M.L.,THOMPSON,D.C.(1995).Oral bioavailability of vancomycin solid-state emulsions.International Journal of Pharmaceutics 117(1):119-122.
[82]IIO,K.,NAKAUCHI,M.,YAMAGAMI,S.,TSUTSUMI,M.,HORI,H.,NARUSE,K.,MITANI,H.,SHIMA,A.,SUZUKI,N.(2005).A novel membrane guanylyl cyclase expressed in medaka(Oryzias latipes)intestine.Comp Biochem Physiol B Biochem Mol Biol 140(4):569-578.
[83]DOGRU,S.T,CALIS,S.,ONER,F.(2000).Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin:in vitro-in vivo evaluation.J Clin Pharm Ther 25(6):435-443.
[84]KHOPADE,A.J.,MAHADIK,K.R.,JAIN,N.K.(1996).Targeting of multiple emulsions to the lungs.Pharmazie 51(8):558-562.
[85]OH,I.,KANG.,Y.G.,LEE,Y B.,SHIN,S.C.,KIM,C.K.(1998).Prolonged release of tegafur from S/O/W multiple emulsion.Drug Dev Ind Pharm 24(10):889-894.
[86]CHARMAN,W.N.,PORTER,C.J.,MITHANI,S.,DRESSMAN,J.B.(1997).Physiochemical and physiological mechanisms for the effects of food on drug absorption:the role of lipids and pH.J Pharm Sci 86(3):269-282.
[87]KHOPADE,A.J.,NANDAKUMAR,K.S.,JAIN,N.K.(1998).Lectin-functionalized multiple emulsions for improved cancer therapy.J Drug Target 6(4):285-292.
[88]MIYAKAWA,T.,ZHANG.,W,UCHIDA,T.,KIM,N.S.,GOTO,S.(1993).In vivo release of water-soluble drugs from stabilized water-in-oil-in-water(W/O/W)type multiple emulsions following intravenous administrations using rats.Biol Pharm Bull 16(3):268-272.
[89]FERREIRA,L.A.M.,SEILLER,M.,GROSSIORD,J.L.,MARTY,J.P.,WEPIERRE,J.(1995).Vehicle influence on in vitro release of glucose:w/o,w/o/w and o/w systems compared.Journal of Controlled Release 33(3):349-356.
[90]BONINA,R,BADER,S.,MONTENEGRO,L.,SCROFANI,C.,VISCA,M.(1992).Three phase emulsions for controlled delivery in the cosmetic field.Int J Cosmet Sci 14(2):65-74.
[91]LEE,J.,PARK,T.G.,CHOI,H.(2000).Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method.Int J Pharm 196(1):75-83.
[92]LIU,R.,MA,G.,MENG.,F.T.,SU,Z.G.(2005).Preparation of uniform-sized PLA microcapsules by combining Shirasu porous glass membrane emulsification technique and multiple emulsion-solvent evaporation method.J Control Release 103(1):31-43.
[93]ADACHI,S.,IMAOKA,H.,HASEGAWA,Y.,MATSUNO,R.(2003).Preparation of a water-in-oil-in-water(W/OAV)type microcapsules by a single-droplet-drying method and change in encapsulation efficiency of a hydrophilic substance during storage.Biosci Biotechnol Biochem 67(6):1376-1381.
[94]MENG.,F.T.,MA,G H.,QIU,W.,SU,Z.G(2003).W/OAV double emulsion technique using ethyl acetate as organic solvent:effects of its diffusion rate on the characteristics of microparticles.J Control Release 91(3):407-416.
[95]QIU,W.,MENG.,F.T.,MA,G H.,SU,Z.G(2003).[The preparation of an artificial red blood cell substitute by W/OAV double emulsion methods].Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao(Shanghai)35(5):467-472.
[96]YAZAN,Y,SEILLER,M.,PUISIEUX,F.(1993).Multiple emulsions.Boll Chim Farm 132(6):187-196.
[97]CHEN,C.C.,TU,Y.Y,CHANG H.M.(1999).Efficiency and protective effect of encapsulation of milk immunoglobulin G in multiple emulsion.J Agric Food Chem 47(2):407-410.
[2]LIPINSKI,C.A.,LOMBARDO,R,DOMINY,B.W.,FEENEY,P.J.(2001).Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev 46(1-3):3-26.
[3]STRICKLEY,R.G(2004).Solubilizing excipients in oral and injectable formulations.Pharm Res 21(2):201-230.
[4]BUGGINS,T.R.,DICKINSON,P.A.,TAYLOR,G(2007).The effects of pharmaceutical excipients on drug disposition.Adv Drug Deliv Rev 59(15):1482-1503.
[5]MAHMUD,A.,XIONG.,X.B.,ALIABADI,H.M.,LAVASANIFAR,A.(2007).Polymeric micelles for drug targeting.J Drug Target 15(9):553-584.
[6]STELLA,V.J.,HE,Q.(2008).Cyclodextrins.Toxicol Pathol 36(1):30-42.
[7]METSELAAR,J.M.,MASTROBATTISTA,E.,STORM,G(2002).Liposomes for intravenous drug targeting:design and applications.Mini Rev Med Chem 2(4):319-329.
[8]DRISCOLL,D.F.(2006).Lipid injectable emulsions:2006.Nutr Clin Pract 21(4):381-386.
[9]BANSAL,T.,MUSTAFA,G.,KHAN,Z.I.,AHMAD,F.J.,KHAR,R.K.,TALEGAONKAR,S.(2008).Solid self-nanoemulsifying delivery systems as a platform technology for formulation of poorly soluble drugs.Crit Rev Ther Drug Carrier Syst 25(1):63-116.
[10]KECK,C.M.,MULLER,R.H.(2006).Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.Eur J Pharm Biopharm 62(1):3-16.
[11]VAN EERDENBRUGH,B.,VAN DEN MOOTER,G.,AUGUSTIJNS,P.(2008).Top-down production of drug nanocrystals:nanosuspension stabilization,miniaturization and transformation into solid products.Int J Pharm 364(1):64-75.
[12]WONG.,J.,BRUGGER,A.,KHARE,A.,CHAUBAL,M.,PAPADOPOULOS,P.,RABINOW,B.,KIPP,J.,NING.,J.(2008).Suspensions for intravenous(IV)injection:a review of development,preclinical and clinical aspects.Adv Drug Deliv Rev 60(8):939-954.
[13]MERISKO-LIVERSIDGE,E.,LIVERSIDGE,G(2008).Drug nanoparticles:formulating poorly water-soluble compounds.Toxicol Pathol 36(1):43-48.
[14]FAHR,A.,LIU,X.(2007).Drug delivery strategies for poorly water-soluble drugs.Expert Opin Drug Deliv 4(4):403-416.
[15]NISHIYAMA,N.,KATAOKA,K.(2006).Current state,achievements,and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.Pharmacol Ther 112(3):630-648.
[16]ATTWOOD,D.,ZHOU,Z.,BOOTH,C.(2007).Polyethylene oxide)based copolymers:solubilisation capacity and gelation.Expert Opin Drug Deliv 4(5): 533-546.
[17]MULLER,R.H.,MADER,K.,GOHLA,S.(2000).Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art.Eur J Pharm Biopharm 50(1):161-177.
[18]MULLER,R.H.,RADTKE,M.,WISSING,S.A.(2002).Nanostructured lipid matrices for improved microencapsulation of drugs.Int J Pharm 242(1-2):121-128.
[19]LASIC,D.D.,PAPAHADJOPOULOS,D.(1995).Liposomes revisited.Science 267(5202):1275-1276.
[20]RIAZ,M.(1995).Review article:stability and uses of liposomes.Pak J Pharm Sci 8(2):69-79.
[21]DATE,A.A.,NAGARSENKER,M.S.(2008).Parenteral microemulsions:an overview.Int J Pharm 355(1-2):19-30.
[22]HAYNES,R.K.(2006).From artemisinin to new artemisinin antimalarials:biosynthesis,extraction,old and new derivatives,stereochemistry and medicinal chemistry requirements.Curr Top Med Chem 6(5):509-537.
[23](1982).Studies on the toxicity of qinghaosu and its derivatives.China Cooperative Research Group on qinghaosu and its derivatives as antimalarials.J Tradit Chin Med 2(1):31-38.
[24]MYINT,H.Y.,ASHLEY,E.A.,DAY,N.P.,NOSTEN,F.,WHITE,N.J.(2007).Efficacy and safety of dihydroartemisinin-piperaquine.Trans R Soc Trop Med Hyg 101(9):858-866.
[25]KLAYMAN,D.L.(1985).Qinghaosu(artemisinin):an antimalarial drug from China.Science 228(4703):1049-1055.
[26]GRACE,J.,AGUILAR,A.,TROTMAN,K.,PEGGINS,J.,BREWER,T.(1998).Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450.Drug Metab Dispos 26(4):313-317.
[27]JUNG,M.,LEE,K.,KIM,H.,PARK,M.(2004).Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents.Curr Med Chem 11(10):1265-1284.
[28]曹智刚,袁守军,陈惠鹏,徐兰平,田增月,韩昌明,丁林茂(2006).双氢青蒿素对肿瘤细胞及肿瘤动物模型的抑制作用.期医学杂志(24).
[29]EFFERTH,T.,MARSCHALL,M.,WANG,X.,HUONG,S.M.,HAUBER,I.,OLBRICH,A.,KRONSCHNABL,M.,STAMMINGER,T.,HUANG,E.S.(2002).Antiviral activity of artesunate towards wild-type,recombinant,and ganciclovir-resistant human cytomegaloviruses.J Mol Med 80(4):233-242.
[30]SUN,W.C.,HAN,J.X.,YANG,W.Y.,DENG,D.A.,YUE,X.F.(1992).[Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro].Zhongguo Yao Li Xue Bao 13(6):541-543.
[31]SINGH,N.P.,LAI,H.(2001).Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells.Life Sci 70(1):49-56.
[32]SADAVA,D.,PHILLIPS,T.,LIN,C.,KANE,S.E.(2002).Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells.Cancer Lett 179(2):151-156.
[33]WANG,Z.S.,CAO,X.L.(1988).[Studies on mutarotation and anomeric conversion of dihydroqinghaosu].Yao Xue Xue Bao 23(8):610-615.
[34]董顺玲,胡家炽,张玉英,张焕宜(1996).高效液相色谱法测定双氢青蒿素含量.药物分析杂志(03).
[35]赵文志,白志川,段淼(2007).双氢青蒿素的指纹图谱研究.中外健康文摘(临床医药版)(06).
[36]HU,F.Q.,JIANG,S.P.,DU,Y.Z.,YUAN,H.,YE,Y.Q.,ZENG,S.(2006).Preparation and characteristics of monostearin nanostructured lipid carriers.Int J Pharm 314(1):83-89.
[37]TONGCHER,O.,SIGEL,R.,LANDFESTER,K.(2006).Liquid crystal nanoparticles prepared as miniemulsions.Langmuir 22(10):4504-4511.
[38]OKOCHI,H.,NAKANO,M.(2000).Preparation and evaluation of w/o/w type emulsions containing vancomycin.Adv Drug Deliv Rev 45(1):5-26.
[39]BENITA,S.,LEVY,M.Y.(1993).Submicron emulsions as colloidal drug carriers for intravenous administration:comprehensive physicochemical characterization.J Pharm Sci 82(11):1069-1079.
[40]SUGIURA,S.,NAKAJIMA,M.,YAMAMOTO,K.,IWAMOTO,S.,ODA,T.,SATAKE,M.,SEKI,M.(2004).Preparation characteristics of water-in-oil-in-water multiple emulsions using microchannel emulsification.Journal of Colloid and Interface Science 270(1):221-228.
[41]WEBER,C.H.,CHICHE,A.,KRAUSCH,G,ROSENFELDT,S.,BALLAUFF,M.,HARNAU,L.,GOTTKER-SCHNETMANN,I.,TONG,Q.,MECKING,S.(2007).Single lamella nanoparticles of polyethylene.Nano Lett 7(7):2024-2029.
[42]GAO,Y.,LI,N.,HILFERT,L.,ZHANG,S.,ZHENG,L.,YU,L.(2009).Temperature-induced microstructural changes in ionic liquid-based microemulsions.Langmuir 25(3):1360-1365.
[43]YI,T.,WAN,J.,XU,H.,YANG,X.(2008).A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs.Eur J Pharm Biopharrn 70(2):439-444.
[44]LI,F.,WANG,T.,HE,H.B.,TANG,X.(2008).The properties of bufadienolides-loaded nano-emulsion and submicro-emulsion during lyophilization.Int J Pharm 349(1-2):291-299.
[45]ABDELWAHED,W.,DEGOBERT,G.,STAINMESSE,S.,FESSI,H.(2006).Freeze-drying of nanoparticles:formulation,process and storage considerations.Adv Drug Deliv Rev 58(15):1688-1713.
[46]NAIL,S.L.,HER,L.M.,PROFFITT,C.P.,NAIL,L.L.(1994).An improved microscope stage for direct observation of freezing and freeze drying.Pharm Res 11(8):1098-1100.
[47]ZHANG,L.,LIU,L.,QIAN,Y.,CHEN,Y.(2008).The effects of cryoprotectants on the freeze-drying of ibuprofen-loaded solid lipid microparticles(SLM).Eur J Pharm Biopharm 69(2):750-759.
[48]NAVARATNAM,V.,MORDI,M.,MANSOR,S.(1997).Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies.J Chromatogr B Biomed Sci Appl 692(1):157-162.
[49]NAIK,H.,MURRY,D.,KIRSCH,L.,FLECKENSTEIN,L.(2005).Development and validation of a high-performance liquid chromatography-mass spectroscopy assay for determination of artesunate and dihydroartemisinin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci 816(1-2):233-242.
[50]RAJANIKANTH,M.,MADHUSUDANAN,K.,GUPTA,R.(2003).An HPLC-MS method for simultaneous estimation of alpha,beta-arteether and its metabolite dihydroartemisinin,in rat plasma for application to pharmacokinetic study.Biomed Chromatogr 17(7):440-446.
[51]SOUPPART,C.,GAUDUCHEAU,N.,SANDRENAN,N.,RICHARD,F.(2002).Development and validation of a high-performance liquid chromatography-mass spectrometry assay for the determination of artemether and its metabolite dihydroartemisinin in human plasma.J Chromatogr B Analyt Technol Biomed Life Sci 774(2):195-203.
[52]SINGH,N.,LAI,H.Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells.Anticancer Res 25(6B):4325-4331.
[53]GABOUREL,J.D.(1972).Drug-protein interactions and their clinical significance.Adv Biol Skin 12:51-60.
[54]COLUSSI,D.,PARISOT,C.,LEGAY,F.,LEFEVRE,G(1999).Binding of artemether and lumefantrine to plasma proteins and erythrocytes.Eur J Pharm Sci 9(1):9-16.
[55]ZHANG H.Y,TANG.,X.,LI,H.Y,LIU,X.L.(2008).A lipid microsphere vehicle for vinorelbine:Stability,safety and pharmacokinetics.Int J Pharm 348(1-2):70-79.
[56]WEIDNER,N.(1995).Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors.Breast Cancer Res Treat 36(2):169-180.
[1]TAKINO,T.,KONISHI,K.,TAKAKURA,Y,HASHIDA,M.(1994).Long circulating emulsion carrier systems for highly lipophilic drugs.Biol Pharm Bull 17(1):121-125.
[2]NAKANO,M.(2000).Places of emulsions in drug delivery.Adv Drug Deliv Rev 45(1):1-4.
[3]FLORENCE,A.T.,WHITEHILL,D.(1982).Stabilization of water/oil/water multiple emulsions by polymerization of the aqueous phases.J Pharm Pharmacol 34(11):687-691.
[4]CLAUSSE,D.,GOMEZ,F.,DALMAZZONE,C.,NOIK,C.(2005).A method for the characterization of emulsions,thermogranulometry:Application to water-in-crude oil emulsion.Journal of Colloid and Interface Science 287(2):694-703.
[5]NAKHARE,S.,VYAS,S.P.(1995).Prolonged release of rifampicin from multiple w/o/w emulsion systems.J Microencapsul 12(4):409-415.
[6]NAKHARE,S.,VYAS,S.P.(1996).Preparation and characterization of multiple emulsion based systems for controlled diclofenac sodium release.J Microencapsul 13(3):281-292.
[7]HOU,W.,PAPADOPOULOS,K.D.(1997).W1/0/W2 and O1/W/02 globules stabilized with Span 80 and Tween 80.Colloids and Surfaces A:Physicochemical and Engineering Aspects 125(2-3):181-187.
[8]YOSHIDA,K.,SEKINE,T.,MATSUZAKI,F.,YANAKI,T.,YAMAGUCHI,M.(1999).Stability of vitamin A in oil-in-water-in-oil-type multiple emulsions.Journal of the American Oil Chemists' Society 76(2):1-6.
[9]GARTI,N.(1998).New trends in double emulsions for controlled release.In The Colloid Science of Lipids,pp.83-92.
[10]JUNGINGER,H.E.(1984).Colloidal structures of O/W creams.Pharm Weekbl Sci 6(4):141-149.
[11]LEVY,M.Y,SCHUTZE,W.,FUHRER,C.,BENITA,S.(1994).Characterization of diazepam submicron emulsion interface:role of oleic acid.J Microencapsul 11(1):79-92.
[12]URSICA,L.,TITA,D.,PALICI,I.,TITA,B.,VLAIA,V.(2005).Particle size analysis of some water/oil/water multiple emulsions.J Pharm Biomed Anal 37(5):931-936.
[13]WANGQI,H.,PAPADOPOULOS,K.D.(1996).Stability of water-in-oil-in-water type globules.Chemical Engineering Science 51(22):5043-5051.
[14]VASILJEVIC.,D.,PAROJCIC.,J.,PRIMORAC.,M.,VULETA,G.(2006).An investigation into the characteristics and drug release properties of multiple W/O/W emulsion systems containing low concentration of lipophilic polymeric emulsifier.International Journal of Pharmaceutics 309(1-2):171-177.
[15]MINORU TOMITA,Y A.,TAMOTSU KONDO,(1982).Viscosity change after dilution with solutions of water-oil-water emulsions and solute permeability through the oil layer.Journal of Pharmaceutical Sciences 71(3):332-334.
[16]OZER,O.,BALOGLU,E.,ERTAN,G.,MUGUET,V.,YAZAN,Y.(2000).The effect of the type and the concentration of the lipophilic surfactant on the stability and release kinetics of the W/O/W multiple emulsions.Int J Cosmet Sci 22(6):459-470.
[17]OZER,O.,MUGUET,V.,ROY,E.,GROSSIORD,J.L.,SEILLER,M.(2000).Stability study of W/O/W viscosified multiple emulsions.Drug Dev Ind Pharm 26(11):1185-1189.
[18]TOKGOZ,N.S.,GROSSIORD,J.L.,FRUCTUS,A.,SEILLER,M.,PROGNON,P.(1996).Evaluation of two fluorescent probes for the characterization of W/O/W emulsions.International Journal of Pharmaceutics 141(1-2):27-37.
[19]HINO,T.,SHIMABAYASHI,S.,TANAKA,M.,NAKANO,M.,OKOCHI,H.(2001).Improvement of encapsulation efficiency of water-in-oil-in-water emulsion with hypertonic inner aqueous phase.J Microencapsul 18(1):19-28.
[20]HILLS,B.P.,MANOJ,P.,DESTRUEL,C.(2000).NMR Q-space microscopy of concentrated oil-in-water emulsions.Magn Reson Imaging 18(3):319-333.
[21]HILLS,B.P.,TANG.,H.R.,MANOJ,P.,DESTRUEL,C.(2001).NMR diffusometry of oil-in-water emulsions.Magn Reson Imaging 19(3-4):449-451.
[22]NORDEN,T.P.,SIEKMANN,B.,LUNDQUIST,S.,MALMSTEN,M.(2001).Physicochemical characterisation of a drug-containing phospholipid-stabilised o/w emulsion for intravenous administration.Eur J Pharm Sci 13(4):393-401.
[23]TERRISSE,I.,SEILLER,M.,RABARON,A.,GROSSIORD,J.L.,MAGNET,A.,HEN-FERRENBACH,C.(1993).Rheology:how to characterize and to predict the evolution of W/O/W multiple emulsions.Int J Cosmet Sci 15(2):53-62.
[24]KAWASHIMA,Y,NIWA,T.,TAKEUCHI,H.,HINO,T.,ITOH,Y,FURUYAMA,S.(1991).Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques.J Pharm Sci 80(5):472-478.
[25]NAKHARE,S.,VYAS,S.P.(1997).Multiple emulsion based systems for prolonged delivery of rifampicin:in vitro and in vivo characterization.Pharmazie 52(3):224-226.
[26]AXEL BENICHOU,A.A.(2007).Recent Developments in O/W/O Multiple Emulsions.In Multiple Emulsions(A.ABRAHAM editor),pp.165-207.
[27]JIM JIAO,D.J.B.(2007).Multiple Emulsion Stability:Pressure Balance and Interfacial Film Strength.In Multiple Emulsions(A.ABRAHAM editor),pp.1-27.
[28]BJERREGAARD,S.,S ERBERG.,I.,VERMEHREN,C.,FROKJAER,S.(1999).Formulation and evaluation of release and swelling mechanism of a water-in-oil emulsion using factorial design.International Journal of Pharmaceutics 193(1):1-11.
[29]N.GARTI(1998).A new approach to improved stability and controlled release in double emulsions,by the use of graft-comb polymeric amphiphiles.Acta Polymerica 49(10-11):606-616.
[30]DAVIS,S.S.,WALKER,I.(1983).Measurement of the yield of multiple emulsion droplets by a fluorescent tracer technique.International Journal of Pharmaceutics 17(2-3):203-213.
[31]OMOTOSHO,J.A.,WHATELEY,T.L.,LAW,T.K.,FLORENCE,A.T.(1986).The nature of the oil phase and the release of solutes from multiple(w/o/w)emulsions. J Pharm Pharmacol 38(12):865-870.
[32]SHIMA,M.,TANAKA,M.,KIMURA,Y.,ADACHI,S.,MATSUNO,R.(2004).Hydrolysis of the oil phase of a W/O/W emulsion by pancreatic lipase.J Control Release 94(1):53-61.
[33]ANNETT KNOTH,I.S.,GERALD MUSCHIOLIK,(2005).Effect of lipid type on water-in-oil-emulsions stabilized by phosphatidylcholine-depleted lecithin and polyglycerol polyricinoleate.European Journal of Lipid Science and Technology 107(12):857-863.
[34]KHAN,A.Y.,TALEGAONKAR,S.,IQBAL,Z.,AHMED,F.J.,KHAR,R.K.(2006).Multiple emulsions:an overview.Curr Drug Deliv 3(4):429-443.
[35]LINDENSTRUTH,K.,MULLER,B.W.(2004).W/O/W multiple emulsions with diclofenac sodium.European Journal of Pharmaceutics and Biopharmaceutics 58(3):621-627.
[36]SHIMA,M.,KOBAYASHI,Y.,FUJII,T.,TANAKA,M.,KIMURA,Y.,ADACHI,S.,MATSUNO,R.(2004).Preparation of fine W/O/W emulsion through membrane filtration of coarse W/O/W emulsion and disappearance of the inclusion of outer phase solution.Food Hydrocolloids 18(1):61-70.
[37]VAN DER GRAAF,S.,SCHRO,C.G.P.H.,BOOM,R.M.(2005).Preparation of double emulsions by membrane emulsification--a review.Journal of Membrane Science 251(1-2):7-15.
[38]BRODIN,A.F.,KAVALIUNAS,D.R.,FRANK,S.G.(1978).Prlonged drug release from multiple emulsions.Acta Pharm Suec 15(1):1-12.
[39]ALLOUCHE,J.,TYRODE,E.,SADTLER,V.,CHOPLIN,L.,SALAGER,J.-L.(2003).Single-and Two-Step Emulsification To Prepare a Persistent Multiple Emulsion with a Surfactant−Polymer Mixture.Industrial & Engineering Chemistry Research 42(17):3982-3988.
[40]LINDENSTRUTH,K.,MULLER,B.W.(2004).W/O/W multiple emulsions with diclofenac sodium.Eur J Pharm Biopharm 58(3):621-627.
[41]FUKUSHIMA,S.,JUNI,K.,NAKANO,M.(1983).Preparation of and drug release from W/O/W type double emulsions containing anticancer agents.Chem Pharm Bull(Tokyo) 31(11):4048-4056.
[42]FUKUSHIMA,S.,NISHIDA,M.,NAKANO,M.(1987).Preparation of and drug release from W/O/W type double emulsions containing anticancer agents using an oily lymphographic agent as an oil phase.Chem Pharm Bull(Tokyo) 35(8):3375-3381.
[43]OKOCHI,H.,NAKANO,M.(2000).Preparation and evaluation of w/o/w type emulsions containing vancomycin.Adv Drug Deliv Rev 45(1):5-26.
[44]JOSCELYNE,S.M.,DH,G.(2000).Membrane emulsification--a literature review.Journal of Membrane Science 169(1):107-117.
[45]KUKIZAKI,M.,GOTO,M.(2007).Preparation and evaluation of uniformly sized solid lipid microcapsules using membrane emulsification.Colloids and Surfaces A:Physicochemical and Engineering Aspects 293(1-3):87-94.
[46]HIGASHI,S.,TABATA,N.,KONDO,K.H.,MAEDA,Y.,SHIMIZU,M.,NAKASHIMA,T.,SETOGUCHI,T.(1999).Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma.J Pharmacol Exp Ther 289(2):816-819.
[47]SUGIURA,S.,NAKAJIMA,M.,YAMAMOTO,K.,IWAMOTO,S.,ODA,T.,SATAKE,M.,SEKI,M.(2004).Preparation characteristics of water-in-oil-in-water multiple emulsions using microchannel emulsification.Journal of Colloid and Interface Science 270(1):221-228.
[48]WHITEHILL,D.,FLORENCE,A.T.(1979).Mechanisms of instability in W/O/W multiple emulsions [proceedings].J Pharm Pharmacol 31 Suppl:3P.
[49]ZHANG.,W.,MIYAKAWA,T.,UCHIDA,T.,GOTO,S.(1992).[Preparation of stable W/O/W type multiple emulsion containing water-soluble drugs and in vitro evaluation of its drug-releasing properties].Yakugaku Zasshi 112(1):73-80.
[50]MUGUET,V.,SEILLER,M.,BARRATT,G.,OZER,O.,MARTY,J.P.,GROSSIORD,J.L.(2001).Formulation of shear rate sensitive multiple emulsions.J Control Release 70(1-2):37-49.
[51]VAZIRI,A.,WARBURTON,B.(1994).Slow release of chloroquine phosphate from multiple taste-masked W/O/W multiple emulsions.J Microencapsul 11(6):641-648.
[52]VAZIRI,A.,WARBURTON,B.(1995).Improved stability of w/o/w multiple emulsions by addition of hydrophilic colloid components in the aqueous phases.J Microencapsul 12(1):1-5.
[53]FECHNER,A.,KNOTH,A.,SCHERZE,I.,MUSCHIOLIK,G.(2007).Stability and release properties of double-emulsions stabilised by caseinate-dextran conjugates.Food Hydrocolloids 21(5-6):943-952.
[54]BJERREGAARD,S.,S ERBERG.,I.,VERMEHREN,C.,FROEKJAER,S.(1999).The effect of controlled osmotic stress on release and swelling properties of a water-in-oil emulsion.International Journal of Pharmaceutics 183(1):17-20.
[55]KAWASHIMA,Y,NIWA,T,TAKEUCHI,H.,HINO,T.,ITO,Y.(1992).Control of prolonged drug release and compression properties of ibuprofen microspheres with acrylic polymer,eudragit RS,by changing their intraparticle porosity [corrected].Chem Pharm Bull(Tokyo)40(1):196-201.
[56]HINO,T,SHIMABAYASHI,S.,TANAKA,M.,NAKANO,M,OKOCHI,H.(2001).Improvement of encapsulation efficiency of water-in-oil-inwater emulsion with hypertonic inner aqueous phase.Journal of Microencapsulation 18(1):19-28.
[57]HINO,T,KAWASHIMA,Y,SHIMABAYASHI,S.(2000).Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy.Advanced Drug Delivery Reviews 45(1):27-45.
[58]FLORENCE,A.T,ROGERS,J.A.(1971).Emulsion stabilization by non-ionic surfactants:experiment and theory.J Pharm Pharmacol 23(A):233-251 concl.
[59]FLORENCE,A.T,ROGERS,J.A.(1971).Emulsion stabilization by non-ionic surfactants:experiment and theory.J Pharm Pharmacol 23(3):153-169 contd.
[60]OPAWALE,F.O.,BURGESS,D.J.(1998).Influence of interfacial rheological properties of mixed emulsifier films on the stability of water-in-oil-in-water emulsions.J Pharm Pharmacol 50(9):965-973.
[61]OPAWALE,F.O.,BURGESS,D.J.(1998).Influence of Interfacial Properties of Lipophilic Surfactants on Water-in-Oil Emulsion Stability.J Colloid Interface Sci 197(1):142-150.
[62]JIAO,J.,BURGESS,D.J.(2003).Rheology and stability of water-in-oil-in-water multiple emulsions containing Span 83 and Tween 80.AAPS PharmSci 5(1):E7.
[63]OMOTOSHO,J.A.,WHATELEY,T.L.,FLORENCE,A.T.(1989).Release of 5-fluorouracil from intramuscular w/o/w multiple emulsions.Biopharm Drug Dispos 10(3):257-268.
[64]OMOTOSHO,J.A.,WHATELEY,T.L.,FLORENCE,A.T.(1989).Methotrexate transport from the internal phase of multiple w/o/w emulsions.J Microencapsul 6(2):183-192.
[65]JIAO,J.,RHODES,D.G.,BURGESS,D.J.(2002).Multiple emulsion stability:pressure balance and interfacial film strength.J Colloid Interface Sci 250(2):444-450.
[66]MYERS,S.L.,SHIVELY,M.L.(1993).Solid-state emulsions:the effects of maltodextrin on microcrystalline aging.Pharm Res 10(9):1389-1391.
[67]SHIVELY,M.L.,MYERS,S.(1993).Solid-state emulsions:the effects of process and storage conditions.Pharm Res 10(7):1071-1075.
[68]IWAMOTO,K.,KATO,T.,KAWAHARA,M.,KOYAMA,N.,WATANABE,S.,MIYAKE,Y,SUNAMOTO,J.(1991).Polysaccharide-coated oil droplets in oil-in-water emulsions as targetable carriers for lipophilic drugs.J Pharm Sci 80(3):219-224.
[69]JAGER-LEZER,N.,TERRISSE,I.,BRUNEAU,F.,TOKGOZ,S.,FERREIRA,L.,CLAUSSE,D.,SEILLER,M.,GROSSIORD,J.L.(1997).Influence of lipophilic surfactant on the release kinetics of water-soluble molecules entrapped in a W/O/W multiple emulsion.Journal of Controlled Release 45(1):1-13.
[70]KHOPADE,A.J.,JAIN,N.K.(1998).A stable multiple emulsion system bearing isoniazid:preparation and characterization.Drug Dev Ind Pharm 24(3):289-293.
[71]KHOPADE,A.J.,JAIN,N.K.(1998).Effects of drug concentration in inner aqueous phase and additives in oleaginous phase on release and bioavailability of isoniazid from multiple emulsion.Drug Dev Ind Pharm 24(7):677-680.
[72]KAWASHIMA,Y,CUI,F.,TAKEUCHI,H.,NIWA,T.,HINO,T.,KIUCHI,K.(1995).Improved static compression behaviors and tablettabilities of spherically agglomerated crystals produced by the spherical crystallization technique with a two-solvent system.Pharm Res 12(7):1040-1044.
[73]SHIAU,Y F.(1981).Mechanisms of intestinal fat absorption.Am J Physiol 240(1):G1-9.
[74]PORTER,C.J.,CALIPH,S.M.,CHARMAN,W.N.(1997).Differences in preand post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma.J Pharm Biomed Anal 16(1):175-180.
[75]ONYEJI,C.,OMOTOSHO,J.,OGUNBONA,F.(1991).Increased gastro-intestinal absorption of griseofulvin from w/o/w emulsions.
[76]ONYEJI,C.,ADESEGUN,S.(1995).Influence of viscosity on nitrofurantoin absorption from w/o/w emulsions.
[77]ENGEL,R.H.,RIGGI,S.J.,FAHRENBACH,M.J.(1968).Insulin:intestinal absorption as water-in-oil-in-water emulsions.Nature 219(5156):856-857.
[78]SUZUKI,A.,MORISHITA,M.,KAJITA,M.,TAKAYAMA,K.,ISOWA,K.,CHIBA,Y,TOKIWA,S.,NAGAI,T.(1998).Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid.J Pharm Sci 87(10):1196-1202.
[79]MATSUZAWA,A.,MORISHITA,M.,TAKAYAMA,K.,NAGAI,T.(1995).Absorption of insulin using water-in-oil-in-water emulsion from an enteral loop in rats.Biol Pharm Bull 18(12):1718-1723.
[80]TOORISAKA,E.,ONO,H.,ARIMORI,K.,KAMIYA,N.,GOTO,M.(2003).Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water(S/O/W)emulsion.Int J Pharm 252(1-2):271-274.
[81]SHIVELY,M.L.,THOMPSON,D.C.(1995).Oral bioavailability of vancomycin solid-state emulsions.International Journal of Pharmaceutics 117(1):119-122.
[82]IIO,K.,NAKAUCHI,M.,YAMAGAMI,S.,TSUTSUMI,M.,HORI,H.,NARUSE,K.,MITANI,H.,SHIMA,A.,SUZUKI,N.(2005).A novel membrane guanylyl cyclase expressed in medaka(Oryzias latipes)intestine.Comp Biochem Physiol B Biochem Mol Biol 140(4):569-578.
[83]DOGRU,S.T,CALIS,S.,ONER,F.(2000).Oral multiple w/o/w emulsion formulation of a peptide salmon calcitonin:in vitro-in vivo evaluation.J Clin Pharm Ther 25(6):435-443.
[84]KHOPADE,A.J.,MAHADIK,K.R.,JAIN,N.K.(1996).Targeting of multiple emulsions to the lungs.Pharmazie 51(8):558-562.
[85]OH,I.,KANG.,Y.G.,LEE,Y B.,SHIN,S.C.,KIM,C.K.(1998).Prolonged release of tegafur from S/O/W multiple emulsion.Drug Dev Ind Pharm 24(10):889-894.
[86]CHARMAN,W.N.,PORTER,C.J.,MITHANI,S.,DRESSMAN,J.B.(1997).Physiochemical and physiological mechanisms for the effects of food on drug absorption:the role of lipids and pH.J Pharm Sci 86(3):269-282.
[87]KHOPADE,A.J.,NANDAKUMAR,K.S.,JAIN,N.K.(1998).Lectin-functionalized multiple emulsions for improved cancer therapy.J Drug Target 6(4):285-292.
[88]MIYAKAWA,T.,ZHANG.,W,UCHIDA,T.,KIM,N.S.,GOTO,S.(1993).In vivo release of water-soluble drugs from stabilized water-in-oil-in-water(W/O/W)type multiple emulsions following intravenous administrations using rats.Biol Pharm Bull 16(3):268-272.
[89]FERREIRA,L.A.M.,SEILLER,M.,GROSSIORD,J.L.,MARTY,J.P.,WEPIERRE,J.(1995).Vehicle influence on in vitro release of glucose:w/o,w/o/w and o/w systems compared.Journal of Controlled Release 33(3):349-356.
[90]BONINA,R,BADER,S.,MONTENEGRO,L.,SCROFANI,C.,VISCA,M.(1992).Three phase emulsions for controlled delivery in the cosmetic field.Int J Cosmet Sci 14(2):65-74.
[91]LEE,J.,PARK,T.G.,CHOI,H.(2000).Effect of formulation and processing variables on the characteristics of microspheres for water-soluble drugs prepared by w/o/o double emulsion solvent diffusion method.Int J Pharm 196(1):75-83.
[92]LIU,R.,MA,G.,MENG.,F.T.,SU,Z.G.(2005).Preparation of uniform-sized PLA microcapsules by combining Shirasu porous glass membrane emulsification technique and multiple emulsion-solvent evaporation method.J Control Release 103(1):31-43.
[93]ADACHI,S.,IMAOKA,H.,HASEGAWA,Y.,MATSUNO,R.(2003).Preparation of a water-in-oil-in-water(W/OAV)type microcapsules by a single-droplet-drying method and change in encapsulation efficiency of a hydrophilic substance during storage.Biosci Biotechnol Biochem 67(6):1376-1381.
[94]MENG.,F.T.,MA,G H.,QIU,W.,SU,Z.G(2003).W/OAV double emulsion technique using ethyl acetate as organic solvent:effects of its diffusion rate on the characteristics of microparticles.J Control Release 91(3):407-416.
[95]QIU,W.,MENG.,F.T.,MA,G H.,SU,Z.G(2003).[The preparation of an artificial red blood cell substitute by W/OAV double emulsion methods].Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao(Shanghai)35(5):467-472.
[96]YAZAN,Y,SEILLER,M.,PUISIEUX,F.(1993).Multiple emulsions.Boll Chim Farm 132(6):187-196.
[97]CHEN,C.C.,TU,Y.Y,CHANG H.M.(1999).Efficiency and protective effect of encapsulation of milk immunoglobulin G in multiple emulsion.J Agric Food Chem 47(2):407-410.